Share

Opportunity with Neoplasia journal – Commissioning Editor Oncology (call for applications)

As a partner to ScienceDirect through the European Journal of Cancer (EORTC’s Official Journal), we are pleased to herewith share an exciting opportunity with one of the publisher’s other journals, Neoplasia.

Neoplasia – a peer-reviewed journal of the ScienceDirect family that publishes the results of novel investigations in all areas of oncology research – is currently recruiting for a Commissioning Editor in Oncology.

The role of the Commissioning Editor Oncology will be to attract key individuals as top authors to the journal.

Candidates for the role should have a scientific background in Cancer Research / Oncology (PhD minimum), a good understanding of related & interdisciplinary areas with a view of emerging topics, international connections within/across the scientific community, as well as strong networking capabilities and an interest in scientific publishing.

Deadline for applications is December 18, 2021.

For more information on expectations of the role and details of the application process, read on here.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023